Retinoids and metastatic renal cell carcinoma;Retinoides et cancer du rein metastatique

Annales de Medecine Interne

Volumn 148, Issue 7, 1997, Pages 496-501

  Paule, Bernard ^a   Brion, Nathalie ^b  

^a BICÊTRE HOSPITAL   (France)

^b CENTRE HOSPITALIER DE VERSAILLES   (France)

Author keywords

Metastatic renal cell; R interferon ; Retinoids

Indexed keywords

RECOMBINANT ALPHA INTERFERON; RETINOID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; HUMAN; KIDNEY CARCINOMA; METASTASIS; ORAL DRUG ADMINISTRATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; INTERFERON TYPE I, RECOMBINANT; KIDNEY NEOPLASMS; RETINOIDS;

EID: 0031446187     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. GUDAS LJ. Retinoids, retinoid-responsive genes, cell differentiation, and cancer. Cell Growth Differ 1992 ; 3 : 655-62.
2. MCBURNEY MW, COSTA S, PRATT MAC. Retinoids and cancer ; a basis for differentiation therapy. Cancer Invest 1993 ; 11 : 590-8.
3. SMITH MA, PARKINSON DR, CHESON BD, FRIEDMAN MA. Retinoids in cancer therapy. J din Oncol 1992 ; 10 : 839-64.
4. MILLER WH JR, MOY D, LI A, GRIPPO JF, DMITROVSKY E. Retinoic acid induces down-regulation of several growth factors and protooncogenes in a human embryonal cancer line. Oncogene 1990 ; 5 : 511-7.
5. WARRELL RP, THE H, WANG ZY, DECOS L. Acute promyelocytic leukemia. N Engl J Med 1993 ; 329 : 177-89.
6. CASTAIGNE S, CHOMIENNE C, DANIEL T, BALLERINI P, BERGER R, PENAUX P, DEGOS L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I Clinical results. Blood 1990 ; 76 : 1704.
7. GAREWAL HS. Chemoprevention of Barren's esophagus and oral leukoplakia. Adv Exp Med Biol 1992 ; 320 : 129-36.
8. SCULLY C, BOYLE P. Vitamin A-related coumpounds in the Chemoprevention of potentially malignant oral lesions or carcinoma. EiirJ Cancer 1992 ; 28B : 87-9.
9. LIPPMAN SM, KAVANAGH JJ, PAREDES-ESPINOZA , DELGADILLO-MADRUENO F, PAREDES-CASTILLA P, HONG WK, et al. 13-cis-retinoic acid plus Interferon alpha-2a : highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992 ; 84 : 241-5.
10. TOMA S, PALUMBO R, VIXCENTI M, AITINI E, PAGANINT G, PRONZATO P, et al. Efficacy of recombinant alpha-interferon 2a and 13-cis retinoic acid in the treament of squamous cell carcinoma. Ann Oncol 1994 ; 5 : 463-5.
11. Muss HB. Interferon therapy for renal cell carcinoma. Semin Oncol 1987 ; 13 (Suppl 2) : 36-42.
12. WALADKHANI AR, HUFFMAN W, SCHIEBE M, CLEMANS MR. Pharmacokinetics of retinoic acid in cancer patients. Ann Oncol 1994 ; 5 (Suppl 9) : S33-7.
13. ADAMSON PC, BAILEY J, PLUDA J, POPLACK, DG, BAUZA S, MURPHY RF, et al. Pharmacokinetics of All-trans-retinoic acid administered on an intermittent schedule. J Clin Oncol 1995 ;13: 1238-41.
14. LEE JS, NEWMAN RA, LIPPMAN SM, FOSSELLA FV, CALYAG M, RABER MN, et al. Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adult with solid tumors. J Clin Oncol 1995 ; 13 : 1501-1508.
15. MANNERING GJ, DELORIA LB, ABBOT V. Role of xanthine oxydase in the Interferon mediated depression of the hepatic cytochrome P 450 system in mice. Cancer Res 1988 ; 48: 2107-12.
16. BOXHOMME-FAIVRE L, PAULE B, URIEN S, RUDANT E, BOTTUIS L, PRADEL D, et al. Pharmacokinetics of all-trans retinoic acid (ATRA) in patients with renal cancer concomitantly treated with interferon alpha 2A (IFN). Int. J Pharm 1996 ; 134 : 99-104.
17. SMITH DC, TRUMP DL, ADEDOYIN A et al. Alterations in CYP2C mp activity induced by interferon a2a and all trans retinoic acid. ProcAACR 1994 ; Abst 1462 p243.
18. EVANS R. The steroid and thyroid hormone receptor superfamily. Science 1988 ; 240 : 889-95.
19. PEMRICK SM, LUCAS DA, GRIPPO JF. The retinoid receptors. Leukemia 1994 ; 8 (Suppl 3) : 1-10.
20. CHAMBON P. The retinoid signaling pathway : molecular and genetic analyses. Semin Cell Biol 1994 ; 5 : 115-25.
21. COLLINS SJ, ROBERTSO.V KA, MUELLAR L. Retinoic acid-induced granocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-α). Mol Cell Biol 1990 ; 10 : 2154-63.
22. GERADTS J, CHEN JY, RUSSELL EK , YANKASKAS JR, NIEVES L, MINNA JD. Human lung cancer cell lines exhibit resistance to retinoic acid treatment. Cell Growth Differ 1993 ; 4:799-809.
23. SWISSIIELM K, RYAN K, LEE X, Tsou HC, PEACOCKE M, SAGER R. Down-regulation of retinoic receptor β in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells. Cell Growth Differ 1994 ; 5: 131-41.
24. HARENT H. Retinoic acid receptors in retinoid responsive ovarian cancer cell lines detected by polymerase chain reaction following reverse transcription. B J Cancer 1993 ; 8 : 530-6.
25. MOASSER MM, DEBLASIO A, DMITROVSKY E. Response and resistance to retinoic acid are mediated through the retinoic acid receptor, in human teratocarcinomas. Oncogene 1994 ; 9: 833-40.
26. LOTAN R, DAWSON MI, Zou CC, JONG L, LOTAN D, ZOU CP. Enhanced efficacy of combinations of retinoic acid-and retinoid X receptor-selective retinoids and IFN-A in inhibition of cervical carcinoma cell proliferation. Cancer Res 1995; 55.-232-6.
27. HUFFMAN AD, ENGELSTEIN D, BOGENRIEDER T, PAPANDREOU CM, STECKELMAN E, DAVE A, et al. Expression of retinoic acid receptor β in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis Retinoic-Acid. Clin Cancer Res 1996 ; 2 : 1077-82.
28. ZBAR B, BRAUCH H, TAMADIGE C, LINEHAN M. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature (Lond) 1987 ; 327 : S721-4.
29. ANGLARD P, TORY K, BRAUCH H, WEISS GH, LATIL F, MERINO MJ, et al. Molecular analysis of genetic changes in the origin and development of renal cell carcinoma. Cancer Res 1991 ;57: 1071-7.
30. BOURGEADE MF, BESANCON F. Induction of 2′,5′-oligoadenylate synthase by retinoic acid in two transformed human cell lines. Cancer Res. 1984 ; 44 : 5355-60.
31. HIGUSHI T, HANNIGAN GE, M ALKIN D et al. Enhancement by retinoic acid and dibutyryl cyclic adenosine 3′,5-monophosphate of the differentiation and gene expression of human neuroblastoma cells induced by interferon. Cancer Res 1991 ; 51: 3958-64.
32. NAMUS DM, BOGENRIEDER T, ENGELSTEIN D, BENTEL JM, MILLER WH JR, ALBINO AP. Analysis of retinoid receptors (RAR) and retinoid induced antiproliferative effects alone and in conclusion with interferon-a in human renal cancers : Aberrant RARa transcrit in a retinoid resistant cell line. Proc AACR 1994 ; 55 : Abst 506.
33. VAN DER LEEDE BM, OPDENOORDT T, VAN DEN BRINK CE, EBERTT, VAN DER SAAG FT. Implication of retinoic receptor β in renal cell carcinoma, to J Oncol 1995 ; 6 : 391-400.
34. MOTZER RJ, SCHWARTZ L, MURRAY LAW T, MURPHY BA, HUFFMAN AD, ALBINO AP, et al. Interferon alfa-2a and 13-cis-Retinoic acid renal cell carcinoma : antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 1995 ; 13: 1950-7.
35. CAMPOS D, BALBIANI, COPPOLA F, ESTEVEZ R, ZORI COMBA A, ARRIETA C, et al. Interferon alfa-2a and 13-cis-Retinoic acid (CRA) in advanced renal cell carcinoma, early results. Proc ASCO 1996 ; 75 : Abst 701.
36. ATZPODIEN J, EUER J, PROBST M, DUENSING S, KIRCHNER H, GANSER A. Clinical and pre-clinical role of 13-cis-retinoic acid in renal cell carcinoma : Hannover experience. Proc ASCO 1996 ; 15: Abst 625.
37. MINASIAN LM, MOTZER RJ, GLUCK L, MAZUMDAR M, VLAMIS V, KROWN SE. IFNα-2a in advanced renal cell carcinoma : treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993 ; 11: 1368-75.
38. ESCUDIER B, RAVAUD A, BERTON D, CHEVREAU C, DOUILLARD JY, DIETRICH PY. Phase II study of interferon -alpha and all-trans retinoic acid in metastatic renal cell carcinoma. Proc ASCO 1996 ; 75 : Abst 676.
39. PAULE B, BONHOMME-FAIVRE B, RUDANT E., FERRIER F. Interferon alfa-2a plus tretinoin in patients with metastatic renal cells carcinoma. A pilot study. Am J Health-Syt Pharm. 1997 ; 54 : 190-2.
40. LEFEVRE P, THOMAS G, GOURMEL B, DREUX C, CASTAIGNE S, CIIOMIENNE C. Pharmacokinetics of all-trans RA in patients with acute promyelocytic leukemia. Leukemia 1991 ; 5: 1054-61.
41. MuiNDi J, FRANKEL SR, MILLER WH, JAKUKOVSKI A, SCHEINBERG DA, YOUNG CW, et al. Continous treatment with all-trans RA progressively decreases plasma drug concentration : implications for relapse and resistance in acute prolymphocytic leukemia. Blood 1992 ; 79: 299-305.
42. PITOT HC, RUBIN J.BURCH PB et al. Phase I study of all Trans retinoic acid (NSC 122758) in solid tumors on an intermittent schedule. Proc AACR 1994 ; 35 : Abst 1462.
43. BOLLAG W, HOLDENER EE. Retinoids in cancer prevention and therapy. Ann Oncol. 1991 ; 3 : 513-26.
44. CHOMIENNE C, BALLERINI P, BALITRAND N, et al. Retinoic acid therapy for promyelocytic leukemia. Lancet 1989 ; i : 748-55.
45. BERG WJ, SCHWARTZ L, AMSTERDAM et al. Clinical studies of 13-cis-retinoic acid (CRA) in patients with metastatic renal carcinoma (RCC). PmcASCO 1997 ; 16 : Abst 1162.
46. ADAMSON PC, BOYLAN JF, BALIS FM et al. Time course of induction of metabolism of all-trans retinoic acid and up-regulation of cellular retinoic acid binding protein (CRABP). Cancer Res. 1993 ; 53 : 472-9.
47. BOYLAN JF, GUDAS LJ. The level of CRABP-1 expression influences the amounts and types of all-trans retinoic acid metabolites in F9 teratocarcinoma stem cells. J Biol Chein 1992; 267 .-21486-91.
48. DELVA L, CORNIC, M, BALITRAND D et al. Resistance to alltrans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia. Study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 1993 ; 82 : 2175-81.
49. MIKI S, IWANO M, MIKI Y, YAMAMOTO M, TAY B, YOKOBAWA K, et al. Interleukin-6 (IL6) functions as in vitro autocrine growth factor in renal cell carcinomas. FEBS Letter 1989 ; 250: 607.
50. BLAY JY, BOLON I, ALBERTI L et al. Growth inhibition of renal carcinoma lines by interleukin 6 anti sense oligonu-cleotides : an internal autocrine loop. Proc AACR 1994 ; 55 : Abst 3667.
51. BLAY JY, NEGRIER S, COMBARET V et al Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992 ; 52 : 3317-22.